The Billion-Dollar Molecule: The Quest for the Perfect Drug [NOOK Book]

Overview

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes...
See more details below
The Billion-Dollar Molecule: The Quest for the Perfect Drug

Available on NOOK devices and apps  
  • NOOK Devices
  • NOOK HD/HD+ Tablet
  • NOOK
  • NOOK Color
  • NOOK Tablet
  • Tablet/Phone
  • NOOK for Windows 8 Tablet
  • NOOK for iOS
  • NOOK for Android
  • NOOK Kids for iPad
  • PC/Mac
  • NOOK for Windows 8
  • NOOK for PC
  • NOOK for Mac
  • NOOK Study
  • NOOK for Web

Want a NOOK? Explore Now

NOOK Book (eBook)
$13.11
BN.com price

Overview

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS.

You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.
Read More Show Less

Editorial Reviews

Publishers Weekly - Publisher's Weekly
Freelance writer Werth has taken two complex industries--biotechnology and high finance--and woven them into an intriguing story. The subject of his book is Vertex, a start-up firm headquartered in Cambridge, Mass., that set out to be among the first companies to successfully create and improve drugs through structure-based design, a goal that if attained could mean millions, if not billions, of dollars in revenues. Werth's wide access to Vertex and its executives is evident in his detailed account of what he describes as the ``blood sport'' of big-time science. Vertex is guided through the scientific and financial jungles by Joshua Boger, the founder of the company who is also very much the driving force of Werth's narrative. A compelling side-plot is Boger's relationship with Stuart Schreiber, a Harvard chemistry professor who turned from a colleague into a competitor. While the scientific jargon sometimes slows the pace of the work, most readers will stay the course to learn if Boger achieves his goals of raising funds (he does), discovering an important design-based drug and making a lot of money (coming close on both). (Feb.)
Library Journal
Werth, a freelance writer on science and business issues, chronicles Joshua Boger's start-up of Vertex, a biotechnology company dedicated to the discovery of new drugs. Boger, a successful organic chemist with Merck, left his position as a senior director to establish Vertex. He recruited an exceptional group of researchers with the aim of integrating the most advanced disciplines in molecular biology to develop an immune-suppressing drug used in organ transplants and a potent HIV protease inhibitor to help thwart AIDS. Werth also discusses Vertex's financing and initial public stock offering. Recommended for science and business collections in public libraries and for special libraries in the pharmaceutical industry.-- Bruce Slutsky, New Jersey Inst. of Tech. Lib., Newark
Booknews
Journalist Werth draws on interviews and research to tell the story of Joshua Boger and the pharmaceutical research company he founded and, more broadly, to reveal the human, financial, and scientific dynamics of the whole drug industry. Annotation c. Book News, Inc., Portland, OR (booknews.com)
Barbara Jacobs
In a prose style emulating the speed and freneticism surrounding a marathon, Werth reveals the guts of the not-so-new field of biotechnology by focusing on a Cambridge, Massachusetts, company called Vertex. The company's story reads not like a thriller but like a clash of childish egos. It was started by a biochemist; recruiting top talent, Vertex then found its employees, products, and progress impeded by things both human and not. What began as a search for the ultimate immunosuppressant soon shifted into a drive for venture capital funds and partnerships; a major scientist then defected, and Vertex discovered its future promise lay in developing AIDS, anticancer, and anti-inflammation medicines rather than in immunosuppressants. The behind-the-scenes machinations make riveting reading.
Kirkus Reviews
A you-are-there account of the turbulent early days of Vertex, a high-tech, high-risk biotechnology firm. Werth (a freelance science and business writer) spent nearly four years following the travails of Vertex, where he seemingly had considerable access to its inner workings. His story begins in 1989, shortly after the company was launched with $10 million in venture capital—and with a plan to design superior new drugs, atom by atom if necessary. Vertex's chief, the brilliant and exuberant chemist Joshua Boger, is convinced that the company can design a safer immunosuppressive drug and capture the multimillion-dollar-a- year transplant market. Doing so will require brains, time, and lots of money, but Boger brings together the brains and raises the money that buys the time. Negotiating with pharmaceutical firms in England (Glaxo) and Japan (Chugai), he gives Vertex temporary financial security by striking a deal with Chugai and, in 1991, he takes Vertex public. Meanwhile, back at the lab, it turns out that the scientific side of the firm's endeavors aren't as straightforward as Boger's presentations to would-be investors might suggest: There are complications, rivalries, disappointments, and no end of technical problems, and, at the conclusion of the narrative, Vertex still has no product to sell, although its expectations remain high. Throughout, Werth—adept at explaining both science and business—provides enough history to anchor the present, and peoples his story with memorable characters: Besides the energetic, charismatic Boger and his crew of talented, eccentric, overworked chemists and biologists, notable are Harvard researcher StuartSchreiber—exasperating as a colleague, devastating as a rival—and aging transplant-wizard Thomas Starzl (The Puzzle People, 1992). Colorful, packed with facts, and delivering a clear message: that the risks of investing in biotechnology aren't just high—they're stratospheric.
Read More Show Less

Product Details

  • ISBN-13: 9781439126813
  • Publisher: Simon & Schuster
  • Publication date: 8/20/2013
  • Sold by: SIMON & SCHUSTER
  • Format: eBook
  • Pages: 464
  • Sales rank: 311,330
  • File size: 2 MB

Meet the Author

Barry Werth is an award-winning journalist whose articles have appeared in such publications as The New York Times, Washington Monthly, and GQ, where he is a writer-at-large. Currently at work on an expose about doctors and lawyers, he lives in Northampton, Massachusetts.
Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously
Sort by: Showing 1 – 0 of 1 Customer Reviews
    Sort by: Showing 1 – 0 of 1 Customer Reviews

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)